PURE Bioscience, Inc. in brief
PURE Bioscience, Inc. is a listed company in the FMCG industry, based in El Cajon, California, USA. Its last known market value was $9 M (July 2023); there is no current figure. In the year to July 2026 it had sales of $2 M and a net loss of $2 M. It employs about 10 people. Its largest product and service lines by sales in 2026 were PURE Hard Surface (94%) and SILVERION (6%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About PURE Bioscience, Inc.
We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. This broad-spectrum, non-toxic antimicrobial agent is available in liquid form and various concentrations, distinguished by its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to develop resistance.
Our SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, or EPA, the United States Food and Drug Administration, or FDA, and Health Canada. In addition to manufacturing and distributing these products, we also supply SDC-based formulations as raw material ingredients for personal care products.
From the company's annual report filed with the US SEC: read the report
PURE Bioscience, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2003
- ✎Renamed Pure BioscienceFormerly Innovative Medical Services.
- 2020
- 💰Record revenue of $7 millionFY2020, the highest of the 9 years on record.
Events of PURE Bioscience, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,415 (Jan 2022) · #5,440 (Dec 2022) · #5,458 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -106.9%
- Operating margin
- -89.7%
- Return on equity
- —
- Liabilities / assets
- 637.8%
- Net debt
- $6M
- Revenue growth
- +5.5%
- R&D / revenue
- 14.2%
- Revenue per employee
- $232 K
- Profit per employee
- $-248 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jul 2026 | $2M | +5.5% | $-2M | $-2M | -106.9% |
| Jul 2025 | $2M | +12.2% | $-2M | $-2M | -109.1% |
| Jul 2024 | $2M | +4.8% | $-3M | $-3M | -170.9% |
| Jul 2023 | $2M | +3.3% | $-4M | $-4M | -211.8% |
| Jul 2022 | $2M | -51.1% | $-4M | $-3M | -192.8% |
| Jul 2021 | $4M | -46.5% | $-2M | $-2M | -62.7% |
| Jul 2020 | $7M | +262.3% | $0M | $0M | 0.0% |
| Jul 2019 | $2M | — | $-6M | $-7M | -342.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jul 2026 | $-2M | — | — | $-0.02 | — |
| Jul 2025 | $-2M | — | — | $-0.02 | — |
| Jul 2024 | $-3M | — | — | $-0.03 | — |
| Jul 2023 | $-3M | $0M | $-3M | $-0.04 | — |
| Jul 2022 | $-2M | $0M | $-3M | $-0.04 | — |
| Jul 2021 | $-1M | $1M | $-2M | $-0.03 | — |
| Jul 2020 | $1M | $0M | $1M | $0.00 | — |
| Jul 2019 | $-3M | $0M | $-3M | $-0.09 | — |
Quarterly results
Latest quarter to Jul 2026: revenue $1M (-13.2% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jul 2026.
SEC filings
- Oct 29, 202610-KAnnual report · period to Jul 2026
- Oct 29, 20268-KCurrent reportResults of operations
- Oct 20, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Jun 15, 202610-QQuarterly report · period to Apr 2026
- Jun 15, 20268-KCurrent reportResults of operations
- May 5, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Mar 17, 202610-QQuarterly report · period to Jan 2026
- Mar 17, 20268-KCurrent reportResults of operations
- Feb 20, 20268-KCurrent reportShareholder vote
- Dec 30, 2025DEF 14AProxy statement
- Dec 15, 202510-QQuarterly report · period to Oct 2025
- Dec 15, 20258-KCurrent reportResults of operations
Official filings of PURE Bioscience, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-2 M
- Net income
- $-2 M
For year ending July-2026 · source: SEC filing
Balance sheet
- Total assets
- $1 M
- Total liabilities
- $8 M
- Total equity
- $-6 M
As of July-2026
Insider trading at PURE Bioscience, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Robert F. BartlettCEO, Director | Buyindirect | +50,000 | $0.160 | $8 K | 50,000 | Form 4 |
| filed | Bernard BlotnerDirector | Buyindirect | +10,000 | $0.130 | $1 K | 10,000 | Form 4 |
| filed | Tom Y. LeeChief Executive Officer, Director, 10% owner | Buy | +50,000 | $0.130 | $7 K | 5.00 M | Form 4 |
| filed | IVan ChenDirector | Grant or award | +300,000 | $0.150 | $45 K | 750,000 | Form 4 |
| filed | David RendallDirector | Grant or award | +325,000 | $0.150 | $49 K | 402,371 | Form 4 |
| filed | Tom Y. LeeChief Executive Officer, Director, 10% owner | Grant or awardindirect | +15.74 M | $0.150 | $2.4 M | 29.14 M | Form 4 |
| filed | Tom Y. LeeChief Executive Officer, Director, 10% owner | Grant or awardindirect | +6.00 M | $0.150 | $900 K | 6.00 M | Form 4 |
| filed | Tom Y. LeeChief Executive Officer, Director, 10% owner | Buy | +185,000 | $0.200 | $37 K | 4.95 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: PURE Bioscience, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-8 reverse split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
PURE Bioscience, Inc. scorecard#
Passes 5 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in financial health (0 of 3). Fiscal year 2026.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 6
- ✓Revenue grew in the newest year5.5%Revenue up 5.5% in fiscal 2026.
- ✓Revenue up more than 5% a year over three years7.5%7.5% a year over the three years to fiscal 2026.
- ✓Faster growth over three years than its peers' median7.5%7.5% a year against FMCG's median of 0.4% (30 companies).
- ✗Earnings per share grew in the newest year-0.02 vs -0.02Diluted EPS -0.02 in fiscal 2026 against -0.02 the year before (report's currency).
- ✗Net income higher than five years earlier-$2 M-$2 M in fiscal 2026 against -$2 M in 2021.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2026.
Profitability1 of 4
- ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- ✗Operating margin above its peers' median-89.7%-89.7% against FMCG's median of 5.3% (40 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-89.7%-89.7% in fiscal 2026 against -210.7% in 2023.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.27 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-5.1×Operating income -5.1 times interest in fiscal 2026.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.1%Diluted shares up 4.1% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of FMCG, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2026#
Worked out from PURE Bioscience, Inc.'s statements, beside the median of FMCG.
| Ratio | Trend | 2026 | Median of peers |
|---|---|---|---|
| Operating margin | -89.7% | 5.3% | |
| Net margin | -106.9% | 4.1% | |
| Revenue growth, 3 years a year | 7.5% | 0.4% | |
| Revenue growth | 5.5% | 1.4% |
2of 8on the Piotroski tests of financial strength
- Net loss of $2 million, the 6th loss-making year in a row.
- Shareholders' equity is negative: -$6 million.
- Operating income covers the interest bill only -5.1 times.
- Liabilities due within a year exceed current assets (current ratio 0.27).
PURE Bioscience, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jul 31, 2026 | FY 2025to Jul 31, 2025 | FY 2024to Jul 31, 2024 | FY 2023to Jul 31, 2023 | FY 2022to Jul 31, 2022 | FY 2021to Jul 31, 2021 | FY 2020to Jul 31, 2020 | FY 2019to Jul 31, 2019 | FY 2018to Jul 31, 2018 | FY 2017to Jul 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 2.3+5.3%100% | 2.2+12.4%100% | 2.0+4.5%100% | 1.9+3.2%100% | 1.8−51.0%100% | 3.7−46.5%100% | 6.9+262%100% | 1.9+7.6%100% | 1.8−3.1%100% | 1.8—100% | |
| Cost of revenue | 1.0+10.3%42.9% | 0.9+10.9%40.9% | 0.8−10.5%41.5% | 0.9+6.2%48.4% | 0.9−53.9%47.0% | 1.9−36.0%50.1% | 2.9+298%41.9% | 0.7−4.6%38.1% | 0.8+0.4%43.0% | 0.8—41.5% | |
| Gross profit | 1.3+1.8%57.3% | 1.3+13.1%59.3% | 1.2+18.6%58.9% | 1.0−2.9%51.9% | 1.0−51.8%55.2% | 2.1−48.4%56.1% | 4.0+240%58.1% | 1.2—61.9% | — | — | |
| Research and development | 0.3+5.1%14.3% | 0.3+4.6%14.4% | 0.3+1.7%15.4% | 0.3−6.9%15.9% | 0.3−5.9%17.6% | 0.3+5.3%9.2% | 0.3−9.0%4.7% | 0.4−22.9%18.5% | 0.5−41.1%25.9% | 0.8—42.5% | |
| Selling, general and administrative | 3.1−5.6%133% | 3.3−18.1%148% | 4.0−7.5%204% | 4.3+6.2%230% | 4.1r4.1+0.1%223% | 4.0+9.5%109% | 3.7−42.4%53.4% | 6.4r4.0+22.6%336% | 5.2+0.1%295% | 5.2—286% | |
| Operating expenses | 3.4−4.6%147% | 3.6−17.7%163% | 4.3−11.6%222% | 4.9+4.0%263% | 4.7+7.7%261% | 4.4+9.2%119% | 4.0−40.7%58.1% | 6.8r7.5−23.2%355% | 8.8+12.5%497% | 7.8—428% | |
| Operating income | −2.1—−90.0% | −2.3—−103% | −3.2—−163% | −3.9—−211% | −3.7—−205% | −2.3−57875%−62.5% | 0.0—0.1% | −5.6—−293% | −7.0—−397% | −6.0—−328% | |
| Interest expense and finance costs | 0.4+36.1%17.6% | 0.3+92.9%13.6% | 0.2+1007%7.9% | 0.0+133%0.7% | 0.0+50.0%0.3% | 0.0−20.0%0.1% | 0.0−16.7%0.1% | 0.0−25.0%0.3% | 0.0—0.5% | — | |
| Other non-operating income (expense) | −0.4—−17.3% | −0.1—−5.8% | −0.2—−8.1% | −0.0−108%−1.0% | 0.2—12.9% | −0.0−260%−0.2% | 0.0—0.1% | −1.0—−50.6% | −0.4—−22.5% | −0.3—−13.9% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0r0.0−100%0.0% | 0.00.0%0.1% | 0.00.0%0.0% | 0.00.0%0.0% | 0.00.0%0.1% | 0.00.0%0.1% | 0.0r0.0—0.1% | |
| Net income attributable to shareholders | −2.5—−107% | −2.4—−109% | −3.4—−171% | −4.0—−212% | −3.5—−193% | −2.3−58075%−62.7% | 0.0—0.1% | −6.6—−343% | −7.4—−420% | −6.3—−342% | |
| Earnings per share, basic | -0.02—— | -0.02—— | -0.03—— | -0.04—— | -0.04—— | -0.03—— | 0.00—— | -0.09—— | -0.11—— | -0.10—— | |
| Earnings per share, diluted | -0.02—— | -0.02—— | -0.03—— | -0.04—— | -0.04—— | -0.03—— | 0.00—— | -0.09—— | -0.11—— | -0.10—— | |
| Shares, weighted average (basic) | 116+4.1%— | 112+0.0%— | 112+0.4%— | 111+25.4%— | 89+1.9%— | 87+6.0%— | 82+12.8%— | 73—— | — | — | |
| Shares, weighted average (diluted) | 116+4.1%— | 112+0.0%— | 112+0.4%— | 111+25.4%— | 89+1.9%— | 87+3.0%— | 85+16.1%— | 73+8.3%— | 67+6.0%— | 63—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.6+70.4%47.7% | 0.3−4.3%31.6% | 0.3−68.1%42.7% | 1.1−67.7%60.0% | 3.4+41.9%75.6% | 2.4−37.7%55.5% | 3.8+865%60.7% | 0.4−53.2%20.6% | 0.9−48.1%33.0% | 1.6—42.8% | |
| Receivables | 0.3−29.5%28.0% | 0.5+59.1%44.8% | 0.3+4.6%36.4% | 0.3+41.8%15.6% | 0.2−45.4%4.5% | 0.4−66.2%8.6% | 1.1+192%17.2% | 0.4+35.6%19.3% | 0.3−7.4%10.7% | 0.3—7.8% | |
| Inventory | 0.2+36.9%16.2% | 0.1+152%13.3% | 0.1−36.4%6.8% | 0.1−50.8%4.8% | 0.2−46.1%4.0% | 0.3−39.3%7.7% | 0.5+209%8.7% | 0.2−10.2%9.2% | 0.2−27.8%7.7% | 0.3—7.1% | |
| Current assets | 1.2+13.2%99.3% | 1.0+30.1%99.0% | 0.8−49.8%98.4% | 1.6−58.5%87.9% | 3.9+20.9%86.2% | 3.2−42.6%74.3% | 5.6+435%88.0% | 1.0−28.5%53.9% | 1.5−40.8%56.5% | 2.5—64.2% | |
| Property, plant and equipment | 0.0−27.3%0.7% | 0.0−15.4%1.0% | 0.0−94.1%1.6% | 0.2−64.4%12.1% | 0.6−16.2%13.8% | 0.7+134%17.2% | 0.3−12.7%5.0% | 0.4−21.5%18.7% | 0.5−15.9%17.9% | 0.5—14.3% | |
| Other intangible assets | — | — | — | — | — | 0.4−17.0%8.5% | 0.4−16.6%7.0% | 0.5−19.6%27.4% | 0.7−20.0%25.6% | 0.8—21.5% | |
| Total assets | 1.2+12.8%100% | 1.1+29.3%100% | 0.8−55.2%100% | 1.8−59.3%100% | 4.5+4.2%100% | 4.3−31.9%100% | 6.3+227%100% | 1.9−25.0%100% | 2.6−32.8%100% | 3.8—100% | |
| Accounts payable | 0.8+4.6%68.7% | 0.8+30.4%74.1% | 0.6+42.4%73.5% | 0.4−13.5%23.1% | 0.5−17.7%10.9% | 0.6−55.9%13.8% | 1.3+143%21.3% | 0.6−9.0%28.6% | 0.6+42.7%23.6% | 0.4—11.1% | |
| Current liabilities | 4.4+107%366% | 2.1r0.9+188%200% | 0.7+37.8%89.6% | 0.5−7.5%29.2% | 0.6−40.7%12.8% | 1.0−35.8%22.5% | 1.5+105%23.9% | 0.7−42.4%38.2% | 1.3−49.3%49.7% | 2.5—66.0% | |
| Non-current liabilities | — | — | 2.9+189%361% | 1.0—55.9% | — | — | — | — | — | — | |
| Total liabilities | 7.6+23.0%636% | 6.2+67.7%584% | 3.7+137%450% | 1.6+170%85.1% | 0.6−40.7%12.8% | 1.0−35.8%22.5% | 1.5+104%23.9% | 0.7−42.7%38.4% | 1.3−49.0%50.3% | 2.5—66.3% | |
| Retained earnings | −141—−11859% | −139—−13137% | −137—−16699% | −133—−7301% | −129—−2883% | −126—−2923% | −123—−1953% | −123—−6391% | −117—−4541% | −109—−2859% | |
| Shareholders' equity | −6.4—−536% | −5.1—−484% | −2.9−1153%−350% | 0.3−93.0%14.9% | 3.9+17.3%87.2% | 3.3−30.7%77.5% | 4.8+304%76.1% | 1.2−7.1%61.6% | 1.3−0.7%49.7% | 1.3—33.7% | |
| Total liabilities and equity | 1.2+12.8%100% | 1.1+29.3%100% | 0.8−55.2%100% | 1.8−59.3%100% | 4.5+4.2%100% | 4.3−31.9%100% | 6.3+227%100% | 1.9−25.0%100% | 2.6−32.8%100% | 3.8—100% | |
| Shares outstanding | 130+16.2%— | 112+0.0%— | 1120.0%— | 112+0.4%— | 111+27.7%— | 87+0.2%— | 87+13.5%— | 77+12.4%— | 68+8.2%— | 63—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0+50.0%0.1% | 0.0−98.6%0.1% | 0.1+26.5%7.6% | 0.1−45.1%6.3% | 0.2+23.8%11.7% | 0.2−10.4%4.7% | 0.2−20.3%2.8% | 0.2−15.4%12.6% | 0.3+3.3%16.1% | 0.3—15.1% | |
| Share-based compensation | 0.2+34.0%8.5% | 0.1−31.3%6.7% | 0.2−34.0%10.9% | 0.3−42.9%17.3% | 0.6−32.6%31.3% | 0.8+6.9%22.7% | 0.8−67.9%11.4% | 2.4+3.8%128% | 2.4+120%133% | 1.1—58.4% | |
| Cash from operating activities | −1.7—−75.1% | −2.0—−91.7% | −2.5—−129% | −3.3—−175% | −2.4—−133% | −1.2−274%−31.6% | 0.7—9.7% | −3.0—−157% | −3.9—−219% | −4.6—−249% | |
| Capital expenditure | — | — | — | −0.0—−1.8% | −0.1—−4.5% | −0.5—−14.1% | −0.1—−0.8% | −0.0—−0.4% | −0.0—−1.1% | −0.2—−11.3% | |
| Intangible assets bought | — | — | — | — | — | — | — | −0.0—−0.3% | −0.0—−0.8% | −0.0—−1.1% | |
| Cash from investing activities | — | — | — | −0.0—−1.8% | −0.1—−4.5% | −0.5—−14.1% | −0.1—−0.8% | −0.0—−0.7% | −0.0—−1.9% | −0.2—−12.3% | |
| Shares issued | — | — | — | — | 3.5—193% | — | 2.8+65.5%40.9% | 1.7—89.6% | — | 1.0—57.3% | |
| Cash from financing activities | 2.0−1.3%85.2% | 2.0+12.0%91.0% | 1.8+75.9%91.3% | 1.0−71.0%54.2% | 3.5+1364%193% | 0.2−91.6%6.5% | 2.8+11.0%40.9% | 2.6−18.6%134% | 3.1+154%177% | 1.2—67.4% | |
| Change in cash | 0.2—10.2% | −0.0—−0.7% | −0.7—−38.2% | −2.3−329%−123% | 1.0—55.2% | −1.4−142%−39.2% | 3.4—49.7% | −0.5—−23.7% | −0.8—−44.5% | −3.6—−194% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jul 31, 2026 | Q4 FY2026to Jul 31, 2026 | Q3 FY2026to Apr 30, 2026 | Q2 FY2026to Jan 31, 2026 | Q1 FY2026to Oct 31, 2025 | Q4 FY2025to Jul 31, 2025 | Q3 FY2025to Apr 30, 2025 | Q2 FY2025to Jan 31, 2025 | Q1 FY2025to Oct 31, 2024 | Q4 FY2024to Jul 31, 2024 | Q3 FY2024to Apr 30, 2024 | Q2 FY2024to Jan 31, 2024 | Q1 FY2024to Oct 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 2.3+5.3%100% | 0.7*−13.6%100% | 0.5+3.5%100% | 0.4+13.3%100% | 0.7+27.4%100% | 0.8*+61.7%100% | 0.5+11.1%100% | 0.4+20.3%100% | 0.6−22.7%100% | 0.5*—100% | 0.4—100% | 0.3—100% | 0.7—100% | |
| Cost of revenue | 1.0+10.3%42.9% | 0.3*−1.7%44.2% | 0.2+13.9%46.8% | 0.2+25.6%46.5% | 0.3+11.7%36.5% | 0.3*+48.7%38.8% | 0.2+13.7%42.5% | 0.2+10.1%41.9% | 0.2−17.5%41.6% | 0.2*—42.2% | 0.2—41.6% | 0.1—45.8% | 0.3—39.0% | |
| Gross profit | 1.3+1.8%57.3% | 0.4*−21.2%56.0% | 0.3−4.9%53.2% | 0.2+4.8%53.7% | 0.5+38.5%63.6% | 0.5*+70.2%61.3% | 0.3+9.7%57.9% | 0.2+28.2%58.1% | 0.3−26.5%58.6% | 0.3*—58.3% | 0.3—58.6% | 0.2—54.5% | 0.4—61.6% | |
| Research and development | 0.3+5.1%14.3% | 0.1*+27.4%14.1% | 0.1−13.2%15.6% | 0.1−8.6%16.7% | 0.1+21.1%12.2% | 0.1*+5.8%9.6% | 0.1+18.2%18.6% | 0.1+6.6%20.7% | 0.1−11.3%12.8% | 0.1*—14.6% | 0.1—17.5% | 0.1—23.4% | 0.1—11.1% | |
| Selling, general and administrative | 3.1−5.6%133% | 0.8*+6.6%118% | 0.7−8.8%140% | 0.8−2.8%191% | 0.7−15.7%105% | 0.7*−13.5%95.8% | 0.8−22.2%159% | 0.9−18.2%223% | 0.9−17.9%159% | 0.8*—179% | 1.0—227% | 1.1—328% | 1.1—149% | |
| General and administrative | — | — | 0.7−12.1%129% | 0.8−6.5%178% | — | — | 0.7—152% | 0.8—216% | — | — | — | — | — | |
| Operating expenses | 3.4−4.6%147% | 0.9*+8.5%132% | 0.8−9.2%156% | 0.9−3.3%208% | 0.8−12.9%117% | 0.8*−17.5%105% | 0.9−19.3%177% | 1.0−16.6%243% | 1.0−17.4%172% | 1.0*—206% | 1.1—244% | 1.1—351% | 1.2—161% | |
| Operating income | −2.1—−90.0% | −0.5*—−76.3% | −0.5—−102% | −0.7—−154% | −0.4—−53.6% | −0.3*—−44.0% | −0.6—−119% | −0.7—−185% | −0.6—−113% | −0.7*—−148% | −0.8—−186% | −1.0—−297% | −0.7—−99.0% | |
| Interest expense and finance costs | 0.4+36.1%17.6% | 0.1*+19.1%16.1% | 0.1+35.9%20.9% | 0.1+44.3%22.8% | 0.1+51.6%13.3% | 0.1*+71.2%11.7% | 0.1+90.2%16.0% | 0.1+84.2%17.9% | 0.1+158%11.2% | 0.1*—11.0% | 0.0—9.3% | 0.0—11.7% | 0.0—3.3% | |
| Other non-operating income (expense) | −0.4—−17.3% | −0.1*−2775%−16.2% | −0.1−2750%−20.9% | −0.1—−23.0% | −0.1—−12.0% | 0.0*—0.5% | 0.0—0.8% | −0.1—−18.7% | −0.1—−11.2% | −0.1*—−12.1% | −0.0—−9.1% | −0.0—−11.7% | −0.0—−3.3% | |
| Net income attributable to shareholders | −2.5—−107% | −0.6*—−92.6% | −0.6—−123% | −0.8—−177% | −0.5—−65.6% | −0.3*—−43.5% | −0.6—−119% | −0.8—−204% | −0.7—−124% | −0.8*—−160% | −0.9—−195% | −1.0—−308% | −0.7—−102% | |
| Earnings per share, basic | — | — | -0.01—— | -0.01—— | 0.00—— | — | -0.01—— | -0.01—— | -0.01—— | — | -0.01—— | -0.01r-0.02—— | -0.01—— | |
| Earnings per share, diluted | — | — | -0.01—— | -0.01—— | 0.00—— | — | -0.01—— | -0.01—— | -0.01—— | — | -0.01—— | -0.01r-0.02—— | -0.01—— | |
| Shares, weighted average (basic) | — | — | 111−0.9%— | 112+0.0%— | 112+0.0%— | — | 1120.0%— | 1120.0%— | 1120.0%— | — | 112—— | 112—— | 112—— | |
| Shares, weighted average (diluted) | — | — | 111−0.9%— | 112+0.0%— | 112+0.0%— | — | 1120.0%— | 1120.0%— | 1120.0%— | — | 112—— | 112—— | 112—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.6—47.7% | 0.6+70.4%47.7% | 1.0+82.0%63.1% | 0.2−2.0%25.1% | 0.4+25.4%36.6% | 0.3−4.3%31.6% | 0.5+22.2%51.1% | 0.2−63.7%35.2% | 0.3−76.0%37.4% | 0.3—42.7% | 0.4—48.0% | 0.6—51.3% | 1.4—64.0% | |
| Receivables | 0.3—28.0% | 0.3−29.5%28.0% | 0.2−15.7%15.5% | 0.3+40.0%32.0% | 0.4+4.9%32.8% | 0.5+59.1%44.8% | 0.3+22.6%27.2% | 0.2+5.3%31.4% | 0.4+6.9%40.2% | 0.3—36.4% | 0.2—25.4% | 0.2—15.7% | 0.3—15.4% | |
| Inventory | 0.2—16.2% | 0.2+36.9%16.2% | 0.2+77.1%14.9% | 0.2+225%31.0% | 0.2+229%20.0% | 0.1+152%13.3% | 0.1+77.0%12.4% | 0.1+1.4%13.1% | 0.1−30.8%7.8% | 0.1—6.8% | 0.1—8.0% | 0.1—6.8% | 0.1—4.6% | |
| Current assets | 1.2—99.3% | 1.2+13.2%99.3% | 1.5+48.1%99.4% | 0.8+38.6%98.9% | 1.2+29.1%99.2% | 1.0+30.1%99.0% | 1.0+20.4%99.0% | 0.6−40.1%97.9% | 0.9−55.9%98.6% | 0.8—98.4% | 0.9—94.5% | 0.9—86.5% | 2.1—91.8% | |
| Property, plant and equipment | 0.0—0.7% | 0.0−27.3%0.7% | 0.0−18.2%0.6% | 0.0−25.0%1.1% | 0.0−23.1%0.8% | 0.0−15.4%1.0% | 0.0−78.4%1.0% | 0.0−91.8%2.1% | 0.0−92.9%1.4% | 0.0—1.6% | 0.1—5.5% | 0.1—13.5% | 0.2—8.2% | |
| Total assets | 1.2—100% | 1.2+12.8%100% | 1.6+47.4%100% | 0.8+37.3%100% | 1.2+28.4%100% | 1.1+29.3%100% | 1.1+14.9%100% | 0.6−47.1%100% | 0.9−58.9%100% | 0.8—100% | 0.9—100% | 1.1—100% | 2.3—100% | |
| Accounts payable | 0.8—68.7% | 0.8+4.6%68.7% | 0.7−10.0%46.1% | 0.8+9.6%97.3% | 0.9+22.4%74.1% | 0.8+30.4%74.1% | 0.8+57.9%75.6% | 0.7+71.1%122% | 0.7+10.1%77.7% | 0.6—73.5% | 0.5—55.0% | 0.4—37.7% | 0.7—29.0% | |
| Current liabilities | 4.4—366% | 4.4+107%366% | 3.7+276%235% | 3.1+253%388% | 3.2+247%266% | 2.1r0.9+188%200% | 1.0+45.9%92.0% | 0.9+58.9%151% | 0.9+13.0%98.6% | 0.7—89.6% | 0.7—72.4% | 0.5—50.2% | 0.8—35.8% | |
| Non-current liabilities | — | — | — | — | — | — | — | 4.0+113%693% | 3.5+92.1%380% | 2.9—361% | 2.4—261% | 1.9—171% | 1.8—81.2% | |
| Total liabilities | 7.6—636% | 7.6+23.0%636% | 7.4+26.0%475% | 7.1+45.9%896% | 6.7+52.3%568% | 6.2+67.7%584% | 5.9+91.5%555% | 4.8+101%843% | 4.4+67.9%478% | 3.7—450% | 3.1—333% | 2.4—222% | 2.6—117% | |
| Retained earnings | −141—−11859% | −141—−11859% | −141—−9042% | −140—−17797% | −139—−11759% | −139—−13137% | −139—−13118% | −138—−24056% | −137—−14858% | −137—−16699% | −136—−14765% | −135—−12429% | −134—−5955% | |
| Shareholders' equity | −6.4—−536% | −6.4—−536% | −5.8—−375% | −6.3—−796% | −5.5—−468% | −5.1—−484% | −4.8—−455% | −4.3—−743% | −3.5—−378% | −2.9—−350% | −2.1—−233% | −1.3—−122% | −0.4—−17.0% | |
| Total liabilities and equity | 1.2—100% | 1.2+12.8%100% | 1.6+47.4%100% | 0.8+37.3%100% | 1.2+28.4%100% | 1.1+29.3%100% | 1.1+14.9%100% | 0.6−47.1%100% | 0.9−58.9%100% | 0.8—100% | 0.9—100% | 1.1—100% | 2.3—100% | |
| Shares outstanding | 130—— | 130+16.2%— | 130+16.2%— | 112+0.0%— | 112+0.0%— | 112+0.0%— | 1120.0%— | 1120.0%— | 1120.0%— | 112—— | 112—— | 112—— | 112—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | 0.0*—8.1% | 0.0*—8.2% | 0.0*—11.4% | 0.0—5.2% | |
| Share-based compensation | 0.2+34.0%8.5% | 0.1*+66.7%7.6% | 0.1+66.7%10.9% | 0.1+115%13.1% | 0.0−40.4%4.8% | 0.0*−21.1%3.9% | 0.0+3.1%6.7% | 0.0−57.8%6.9% | 0.1−28.7%10.3% | 0.0*—8.1% | 0.0*—7.3% | 0.1*—19.7% | 0.1—11.1% | |
| Cash from operating activities | −1.7—−75.1% | −0.4*—−62.8% | −0.5*—−92.5% | −0.6*—−137% | −0.3—−35.4% | −0.5*—−59.8% | −0.5*—−105% | −0.5*—−139% | −0.5—−90.6% | −0.6*—−126% | −0.6*—−140% | −0.9*—−272% | −0.4—−61.3% | |
| Cash from financing activities | 2.0−1.3%85.2% | 0*−100%0.0% | 1.3*+47.4%248% | 0.4*−7.5%83.5% | 0.4−30.0%49.5% | 0.3*−50.0%32.8% | 0.9*+70.0%174% | 0.4*—102% | 0.5−36.3%90.1% | 0.5*—106% | 0.5*—114% | 0*—0.0% | 0.8—109% | |
| Change in cash | 0.2—10.2% | −0.4*—−62.8% | 0.8*+132%155% | −0.2*—−53.3% | 0.1—14.1% | −0.2*—−27.0% | 0.3*—69.1% | −0.1*—−36.8% | −0.0−101%−0.5% | −0.1*—−19.7% | −0.1*—−26.1% | −0.9*—−272% | 0.3—48.1% | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jul 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What PURE Bioscience, Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$2 M100%+5.5%
- PURE Hard Surface$2 M94%+9.0%
- SILVERION$0 M5.8%-35%
Business segments
- Single Reportable$2 M100%+5.5%
Source: SEC annual report (XBRL data) · as of Jul 31, 2026
Events at PURE Bioscience, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 5 · New debt 3 · Unregistered share sale 5 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 29, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2016 | $1 M | Private placement after listing | Under $2 million | 7 | equity, options | SEC |
| Nov 2015 | $2 M | Private placement after listing | $2 to $10 million | 13 | equity, options | SEC |
| Oct 2015 | $6 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Aug 2014 | $10 M | Private placement after listing | $2 to $10 million | 28 | equity, options | SEC |
| Jan 2014 | $1 M | Private placement after listing | Under $2 million | 15 | equity | SEC |
| Dec 2013 | $1 M | No. 4 | Under $2 million | 8 | equity | SEC |
| Oct 2013 | $2 M | No. 3 | $2 to $10 million | 40 | equity | SEC |
| Aug 2013 | $1 M | No. 2 | Under $2 million | 22 | equity | SEC |
| Oct 2010 | $2 M | No. 1 | $2 to $10 million | 11 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How PURE Bioscience, Inc. compares in FMCG
- Revenue$2 M · higher than 2% of 104
- Net margin-106.9% · higher than 3% of 103
- Revenue growth5.5% · higher than 73% of 46
Peer comparison · FMCG
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PURE Bioscience, Inc.🇺🇸 | $9 M | — | -106.9% | +5.5% |
| The Procter & Gamble Company🇺🇸 | $372.2 B | 23.2× | 18.2% | +3.3% |
| L'Oréal S.A.🇫🇷 | $241.7 B | 33.3× | 13.9% | +5.5% |
| Unilever PLC🇬🇧 | $135.7 B | 12.7× | 18.8% | +0.3% |
| Colgate-Palmolive Company🇺🇸 | $74.8 B | 36.4× | 9.7% | +1.4% |
| Hindustan Unilever Limited🇮🇳 | $52.2 B | 32.2× | 23.6% | — |
| Reckitt Benckiser Group PLC🇬🇧 | $44.3 B | 10.2× | 22.4% | +3.3% |
| Haleon plc🇬🇧 | $42.6 B | 19.4× | 15.1% | +1.2% |
| The Estée Lauder Companies Inc.🇺🇸 | $39.6 B | 107.6× | 2.4% | +5.0% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- The Procter & Gamble Company$372.2 B
- L'Oréal S.A.$241.7 B
- Unilever PLC$135.7 B
- Colgate-Palmolive Company$74.8 B
- Hindustan Unilever Limited$52.2 B
- Reckitt Benckiser Group PLC$44.3 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending July-2026
- Balance sheet:
- As of July-2026
- Employees:
- As of October 29, 2026
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PURE Bioscience, Inc.? Verify and update this profile — free
Show PURE Bioscience, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.